Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.
about
An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes MellitusNew Molecular Insights of Insulin in Diabetic CardiomyopathyInsulin resistance and hyperinsulinaemia in diabetic cardiomyopathyEarly Cellular Changes in the Ascending Aorta and Myocardium in a Swine Model of Metabolic SyndromeMitochondrial Calpain-1 Disrupts ATP Synthase and Induces Superoxide Generation in Type 1 Diabetic Hearts: A Novel Mechanism Contributing to Diabetic CardiomyopathyGestational diabetes is characterized by reduced mitochondrial protein expression and altered calcium signaling proteins in skeletal muscleHyperglycemia and hyperlipidemia blunts the Insulin-Inpp5f negative feedback loop in the diabetic heartLack of Association Between Toxoplasma gondii Infection and Diabetes Mellitus: A Matched Case-Control Study in a Mexican Population.Diabetic cardiomyopathy: where we are and where we are going.Metabolic and Biochemical Stressors in Diabetic Cardiomyopathy.Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms.The critical role of Astragalus polysaccharides for the improvement of PPARα [ correction of PPRAα]-mediated lipotoxicity in diabetic cardiomyopathyRutin alleviates diabetic cardiomyopathy in a rat model of type 2 diabetes.Hydrogen sulfide attenuates high fat diet-induced cardiac dysfunction via the suppression of endoplasmic reticulum stress.Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats.Muscle as a "mediator" of systemic metabolismMolecular Mechanisms of Retinoid Receptors in Diabetes-Induced Cardiac Remodeling.Glucagon-Like Peptide 1 Protects against Hyperglycemic-Induced Endothelial-to-Mesenchymal Transition and Improves Myocardial Dysfunction by Suppressing Poly(ADP-Ribose) Polymerase 1 Activity.Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice.Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and ratsSuccessful metabolic adaptations leading to the prevention of high fat diet-induced murine cardiac remodelingDefective insulin signaling and mitochondrial dynamics in diabetic cardiomyopathy.Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.Retinoic acid protects cardiomyocytes from high glucose-induced apoptosis through inhibition of NF-κB signaling pathwayMalondialdehyde and 4-hydroxynonenal adducts are not formed on cardiac ryanodine receptor (RyR2) and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2) in diabetesDiabetic cardiomyopathy and metabolic remodeling of the heart.Investigation of the Protective Effects of Phlorizin on Diabetic Cardiomyopathy in db/db Mice by Quantitative Proteomics.Molecular Basis of Insulin Resistance: The Role of IRS and Foxo1 in the Control of Diabetes Mellitus and Its ComplicationsGene transfer of human neuregulin-1 attenuates ventricular remodeling in diabetic cardiomyopathy rats.Adipocyte-specific loss of PPARγ attenuates cardiac hypertrophy.Present Insights on Cardiomyopathy in Diabetic Patients.Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease--an overview.Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications.A 56-year-old man with co-prevalence of Leriche syndrome and dilated cardiomyopathy: case report and review.Vitamins and their derivatives in the prevention and treatment of metabolic syndrome diseases (diabetes).Cross-Talk Between Insulin Signaling and G Protein-Coupled Receptors.Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention.Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy.
P2860
Q26740006-EB687FBE-A1AC-4FE3-977D-0318C89B9F64Q26752678-B517F75B-3EDC-46E2-824D-EEF6BC7D4136Q26775037-D5DD2DCA-1EBA-4EDC-8C76-266084C67A1FQ27332290-34DDBE75-0A80-4A3C-8E27-2D78B3EF2880Q28397064-2C133FAF-F557-4435-9875-297325CE126AQ28542951-E4221897-99F6-429F-8CD3-B10F8A5093C7Q28583594-42C40B20-FB27-4422-8B8A-31761D15E6D5Q33625212-CEBCB3CD-17E7-4DE8-8520-425F8818CE31Q33690717-08323886-E3A2-49B7-829C-C67B4F38DBE0Q33740554-4E60491E-B98D-4893-9698-9842FEEEBBEEQ33865096-654AB676-D9EA-4B09-9823-EB8A69AD32EEQ34437557-0ACFF7E7-48F1-45A1-95EE-83B1D63F1240Q34795583-E4B4E4B8-5F52-4A79-BFA9-8FE1FD9D4308Q35181153-9038733F-0F17-4063-A4FB-407D2C8BAE28Q35207833-2C7047BB-2D6D-4AA1-B695-2847C4516028Q35429223-F118A709-2CCA-4B50-ABCF-6B79B8F13CE4Q35667311-C7D390A5-0252-4587-A0FE-3ED71C45403AQ35707164-9B55FF7F-035C-4816-B28F-AD87AAF0C388Q35780290-26C0551D-1654-4264-83C0-36ACBB7AE370Q35829973-A925897A-183C-4A2A-B920-64C21E209B36Q36091987-EAF7B4D6-5600-4873-83FE-0515EE9DE7AAQ36225147-743E5F1F-E20E-492E-B7B4-1FA65C713CBEQ36312752-5B47953D-11DA-4F53-8D99-460F95B05766Q36315787-BB82B430-57F2-4E6F-8579-9C7B47A1A5A9Q36485424-776EB159-16DC-43BE-B7FA-8B75DA379ADFQ36672871-D40C2352-EF42-4BE5-BCDB-BF0B91930CF1Q36825677-4A15B3A9-61D2-4A39-AECA-DFDB57D8FB80Q37149334-B35C1F46-02D9-4AB3-BB75-188CDA0B337DQ37288691-D47D6836-A70E-479F-8247-F8F360AC7EB4Q37316215-D51AFD2F-CE00-4F01-8D16-0B35C0180532Q37402793-115FED43-721F-4A32-ACB9-DA99B662DDE9Q37991017-DC80CC00-7A49-46DB-BA6E-56A0C07984CBQ38170474-6B1FB482-65D1-4579-8988-49906B7973FDQ38171685-7B1FFF54-15E3-448E-B2EF-BB3D6D427C71Q38451830-DE3FE3F8-2B34-444D-8756-C1A283A97B91Q39193265-CA4DB452-9172-47B6-9CCA-EB81C263A879Q39201286-4DB8B120-F026-4644-8ABC-D695C363EAA5Q39300236-4E9F4424-11EF-4ED3-91E4-496B81E32213Q39620719-2D9A91B8-0DDD-4004-8742-C322E475A816Q40122924-28352866-6CE0-40DD-9A1F-0258816B253E
P2860
Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.
@en
Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.
@nl
type
label
Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.
@en
Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.
@nl
prefLabel
Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.
@en
Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.
@nl
P2093
P2860
P1476
Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.
@en
P2093
Joseph A Hill
Pavan K Battiprolu
Thomas G Gillette
Zhao V Wang
P2860
P304
P356
10.1016/J.DDMEC.2010.08.001
P577
2010-01-01T00:00:00Z